Tuesday, March 31, 2020

Pharmacovigilance Market Forecast, Size – Rising New Technologies Research Forecast to 2025

Market Highlights
According to MRFR analysis, Pharmacovigilance Market Forecast is expected to register a CAGR of 14.1% during the forecast period of 2019 to 2025 and accounts for USD 4321.86 Million 2018.
Pharmacovigilance supports safe and appropriate use of drugs by identifying risk factors for the development of adverse drug reactions (ADR), promoting the detection of previously unknown ADR and their interactions with known ADR.
The market is dominated by numerous established players. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, on May 16, 2019, Accenture launched INTENT to improve the continuity and flow of data across life sciences enterprises, supporting the delivery of ground-breaking treatments for patients.
Segmentation
The Global Pharmacovigilance Market has been segmented based on the clinical trial phase, service provider, type, and end-user.
The market, based on the clinical trial phase, has been divided into phase IV, phase III, phase II, phase I, and pre-clinical. Phase IV segment dominated the pharmacovigilance market as adverse drug reactions are majorly detected in this phase. Whereas, phase III is expected to witness the fastest growth.
The global pharmacovigilance market has been segmented, on the basis of service provider, into in-house and contract outsourcing. Contract outsourcing dominated the global pharmacovigilance market and expected to witness the fastest growth. Contract manufacturing serves multiple customers and thus can acquire raw materials at a reduced cost, benefiting from the economies of scale.  
The market, based on type, has been divided into spontaneous reporting, cohort event monitoring, intensified ADR reporting, targeted spontaneous reporting, and EHR mining. The spontaneous reporting held largest market share in 2018. Spontaneous reporting is a passive approach to pharmacovigilance as it entirely relies on the motivation of individuals to report suspected ADRs to a local or national pharmacovigilance center.
In terms of end-user, the global pharmacovigilance market has been segmented into hospitals, research organizations, pharmaceutical companies, and others. Hospitals take up the largest share due to an increase in the number of hospital admissions due to ADRs.
Key Players
Some of the key players in the Global Pharmacovigilance Market are Accenture (Ireland), ArisGlobal (US), BioClinica (US), Capgemini (France), Conquest Group BV (Netherlands), Cognizant (US), IBM Corporation (US), ICON PLC (Ireland), IMEDGlobal (US), ITClinical (Portugal), Laboratory Corporation of America Holdings (US), PAREXEL International Corporation (US), TAKE Solutions Ltd (India), United BioSource Corporation (US), and Wipro Ltd (India).
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the high spending by the pharmaceutical industry. The pharmacovigilance market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European Pharmacovigilance market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Pharmacovigilance market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing prevalence of chronic conditions and rising cases of ADRs and medication errors, the market in Asia-Pacific is expected to be the fastest-growing. The pharmacovigilance market in the Middle East & Africa has been divided into the Middle East and Africa.
Posted by at No comments:

Vision Care Market Forecast Latest Innovations, Drivers and Industry Key Events 2018 – 2025

Market Highlights
According to MRFR analysis, Vision Care Market Forecast is expected to register a CAGR of 4.48% during the forecast period of 2019 to 2025 was valued at USD 52,000 Million in 2018.
Vision care plays an essential role in ophthalmology. The vision care products and procedures are used for treating the indications. For instance, the prevalence of vision impairment is about 1,000 million cases globally. The vision care has benefited resolve ophthalmic disorders and diseases.
However, unawareness about the vision care products and services is likely to hamper the growth of the global vision care market during the forecast period.
Several market players currently dominate the global vision care market. The key players are involved in product launches and strategic collaborations to strengthen their market positions.

Segmentation
The global vision care market has been segmented based on product type, indication, treatment, and end user.
The market, based on product type, has been divided into contact lenses, eyeglasses, intraocular lenses (IOL), and others. The contact lens segment has been further classified as corrective lens, therapeutic lens, cosmetic, and lifestyle-oriented lens. The contact lens is likely to hold the maximum market share in the global vision care market, owing to the unwillingness of people to use the eyeglasses. Eyeglasses are further segmented single vision, bifocal, progressive, sunglasses. The intraocular lens (IOL) segment is further segmented into Premium, Traditional/Mono-focal, Phakic.
The global vision care market on the basis of indication has been segregated into refractive error cataract, glaucoma, diabetic retinopathy, amblyopia, dry eyes, and others.
On the basis of treatment, the global vision care market is mainly segmented into Surgery, medication, and others.
The end user segment of the market consists of eye hospitals & clinics, ambulatory surgery centers, optical stores, and others. Optical stores segment is expected to hold the largest share of the market as these centers are primary locations for patients utilize the vision care products.


Key Players
Some of the key players in the Global Vision Care Market are Cadila Healthcare (Zydus Pharmaceuticals, Inc.), Johnson & Johnson Services, Inc., Rayner Surgical Group Limited (Rayner Intraocular Lenses Limited), Menicon, Carl-Zeiss-Stiftung (Carl Zeiss). ESSILORLUXOTTICA, Bausch Health (Bausch & Lomb Incorporated), The Cooper Companies, Inc (Cooper Vision), NOVARTIS AG.

Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is anticipated to hold the largest market share owing to the increasing awareness about advanced vision care procedures. The vision care market is divided into the Americas has further been branched into North America and Latin America, with the North American market being divided into the US and Canada.
The vision care market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Asia-Pacific is anticipated to hold the largest market share owing to the increasing number of increasing geriatric population and rising adoption of technological advancements in developing regions. The European vision care market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The vision care market in the Middle East & Africa has been divided into the Middle East and Africa.
Posted by at No comments:

Monday, March 30, 2020

Glioblastoma Market Size, significant challenges, Specifications, Analysis Forecast To 2021



Glioblastoma Market: Information by Type (Primary Glioblastoma and Secondary Glioblastoma), by Treatment (Surgical Procedure, Radiation Therapy, Chemotherapy and others), by End User (Hospitals, Specialty Clinics & Centers and others) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2025
Market Highlights
The Global Glioblastoma Market is expected to register a CAGR of 7.40% during the forecast period with a market value of USD 1,643.4 Million till 2025. Glioblastoma is a malignant grade IV tumor. The increasing incidence rates, the rise in product approvals, and growing research in the field are projected to drive the growth of the global glioblastoma market. On the other hand, the termination of many clinical trial drug candidates is anticipated to hamper the growth of the market.
Segment Analysis
The global glioblastoma market has been divided based on type, treatment, and end user. The market, based on type, has been segregated into primary glioblastoma and secondary glioblastoma. Based on treatment, the glioblastoma market has been divided into surgical procedure, radiation therapy, chemotherapy, and others. The global glioblastoma market, based on end user, has been categorized as hospitals, specialty clinics and centers, and others.
Regional Analysis
The global glioblastoma market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is likely to hold the largest share of the global glioblastoma market during the assessment period. The increasing incidence rate of glioblastoma and high funding for research & development projects in the US and Canada are likely to support the dominance of the Americas during the forecast period. The approval of drugs in these countries help in maximizing the growth of the market in this region as well.
The Europe market established substantial growth in the market due to the increasing number of clinical trials in this region.
Asia-Pacific is estimated to be the fastest-growing region in the global market due to the huge patient population, improving healthcare infrastructure, and growing per capita disposable incomes.
The glioblastoma market in the Middle East & Africa is expected to witness gradual growth due to the increasing availability of new treatment methods.
Market Players
MRFR recognizes the following companies as the key players in the global glioblastoma market— F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (US), Arbor Pharmaceuticals, LLC (US), Sun Pharmaceutical Industries Ltd (India), Merck & Co., Inc. (US), and Teva Pharmaceutical Industries Ltd (Israel).
Key Findings of the Study
  • The Global Glioblastoma Market is estimated to grow at USD 1,643.4 Million by 2025 at a CAGR of 7.40% during the assessment period
  • Americas accounted for the largest share of the global market due to the presence of key market players and increasing prevalence of glioblastoma in the US and Canada
  • Based on type, the primary glioblastoma segment accounted for the largest market share of 3% in 2018
  • Based on treatment, the surgical procedure segment accounted for the largest market share of 2% in 2018
  • On the basis of end user, the hospitals segment accounted for the largest market share of 46% in 2018

Posted by at No comments:

Immunosuppressive Drugs Market Share Pegged for Robust Expansion During 2014 to 2023



Market Analysis 

Immunosuppressants are medicines or drugs that lower the ability of the body to reject a transplanted organ. They are also known as anti-rejection drugs. 

Various factors are propelling the Immunosuppressive Drugs Market Share growth. These factors, as per the new Market Research Future report, include the growing rate of autoimmune diseases, growing need for organ transplantation, increasing rates of organ failure, increasing use of tissue engineering in organ transplant, and burgeoning demand for organ replacement. 

On the flip side, stem cell therapy used as an alternative to organ transplantation, lack of awareness regarding immunosuppressive drugs, shortage of donors for organ transplant, high drug cost, and uncertainty of the action of these drugs on complex organ transplantations are factors that may deter the Immunosuppressive Drugs Market Share growth over the forecast period. 

Market Segmentation 

The MRFR report provides an all-inclusive segmental analysis of the Immunosuppressive Drugs Market Share on the basis of application, end user, drug type, and route of administration. 

Based on drug type, the Immunosuppressive Drugs Market Share is segmented into IMDH inhibitors, mTOR inhibitors, antiproliferative agents, corticosteroids, calcineurin inhibitors, and others. Of these, the calcineurin inhibitors segment will lead the market over the forecast period for their high efficacy.

Based on the route of administration, the Immunosuppressive Drugs Market Share is segmented into oral, intravenous, and others. Of these, the intravenous segment will dominate the market over the forecast period.

Based on the application, the Immunosuppressive Drugs Market Share is segmented into organ transplants, autoimmune disease, and others. Of this, the autoimmune disease segment will have the maximum share in the market during the forecast period, chiefly due to the increasing prevalence of autoimmune diseases, especially systemic lupus erythematosus, multiple sclerosis, and rheumatoid arthritis.

Based on the end user, the Immunosuppressive Drugs Market Share is segmented into organ transplant centers, hospitals and clinics, and others. Of these, hospitals and clinics will have the largest share in the market over the forecast period, chiefly due to the burgeoning number of hospitals in the developing economies coupled with the growing number of patient admissions. 

Regional Analysis 

By region, the Immunosuppressive Drugs Market Share report covers the latest trends and growth opportunities across the Americas, the Middle East and Africa, Europe, and the Asia Pacific. Of these, the Americas will lead the market over the forecast period. Factors aiding the growth of the Immunosuppressive Drugs Market Share in the region include the increasing prevalence of autoimmune diseases, the growing number of organ transplants, large-scale investments in research and development, and technological advancements.

The Immunosuppressive Drugs Market Share in Europe is predicted to have a healthy growth over the forecast period. This is firstly due to the increasing incidence of autoimmune diseases, especially in Western Europe and secondly due to the growing number of transplants in the region.

The Immunosuppressive Drugs Market Share in the APAC region is predicted to grow at the fastest pace over the forecast period. Factors aiding the growth of the Immunosuppressive Drugs Market Share in the region include an increase in medical tourism, the presence of well-established healthcare industry, and a high population.

The Immunosuppressive Drugs Market Share in the MEA is predicted to have a small share in the market over the forecast period for having an underdeveloped organ transplant market and the less incidence of autoimmune diseases.


Key Players 

Notable players profiled in the Immunosuppressive Drugs Market Share report include Zydus Cadila (India), Actavis, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), Mylan Laboratories Inc. (US), Glenmark Pharmaceuticals, Inc (India), Bristol-Myers Squibb Company (US), GlaxoSmithKline PLC (UK), Genzyme Co. (US), F. Hoffmann-La Roche AG (Switzerland), Astellas Pharma (Japan), and Accord Healthcare (US).

Industry News

October 2019: Lupin has introduced Mycophenolate Mofetil Capsules USP, a generic version of Roche’s CellCept. These are antimetabolite immunosuppressant that is indicated for prophylaxis of organ rejections in liver transplant, kidney transplant, and allogenic kidney recipients and must be used together with other forms of immune suppressants.
Posted by at No comments:

Cbd Oil Market Insights: Growth Factors, Market Drivers, Segmentations, Key Players, Analysis & Forecast by 2024


CBD Oil (Cannabidiol Oil) Market: Information by Type (Hemp-Derived & Marijuana-Derived), Application (Cosmetics Industry, Food Industry, Pharmaceuticals Industry & Others) and Region (Americas, Europe, Asia-Pacific and Middle East &Africa) - Global Forecast till 2024


Market Analysis

The Cbd Oil Market is likely to touch USD 3782.32 million at a 38.45% CAGR between 2015-2023, as per the latest Market Research Future (MRFR) report. CBD or cannabidiol oil is derived from cannabis. It is a form of CBD, the chemicals that are found naturally in marijuana plants. The best part, despite coming from marijuana plants, it does not create any intoxication or a high effect, which results from other cannabinoids, called THC. Marijuana-derived types and hemp-derived are the two types of CBD oil. It has wide applications, including cosmetics, food, pharmaceuticals, among others. 

Numerous factors are adding to the global CBD oil market growth. These factors, according to the recent MRFR report, include increasing incidence of chronic diseases and associated complications, legalization of CBD, and increasing expenditure for cannabinoid research. 

On the contrary, strict government policies and adverse effects of CBD are factors that may limit the global CBD oil market growth over the forecast period. 

Market Segmentation

The MRFR report provides an inclusive segmental analysis of the global CBD oil market based on application and type. 

By type, the global CBD oil market is segmented into marijuana-derived types and hemp-derived types. Of these, hemp-derived CBD oil will lead the market over the forecast period. It is predicted to touch USD 2,092.97 million by 2024. The majority of the CBD-based legal products in this market are hemp-based. 

By application, the global CBD oil market is segmented into cosmetics, food, pharmaceuticals, and others. Of these, cosmetics will have major growth in the market for the non-psychoactive and anti-inflammatory properties of CBD. Besides, beauty products that are CBD infused are a key trend today. 


Regional Analysis

By region, the global CBD oil market report covers the recent trends and growth opportunities across the Americas, Europe, the Asia Pacific (APAC), and the Middle East and Africa (MEA). Of these, the Americas will dominate the market over the forecast period for the rising consumption of CBD products. Besides, the presence of key players in the US, increasing awareness about CBD oil usage, efficient distribution channels resulting in easy availability, and availability of different CBD based products are also adding to the global CBD oil market growth in the region. 

The global CBD oil market in Europe is predicted to hold the second-largest share in the CBD oil market over the forecast period for the increasing awareness of clinical applications of cannabis. 

The global CBD oil market in the APAC region is predicted to grow at the highest CAGR over the forecast period for the setting up of hemp manufacturing plants in China, which is the largest cultivator of hemp. Industry players in the personal care & cosmetics industry are targeting emerging economies to enhance their sales and profitability. Besides, the legalization of cannabis is also adding to the market growth. 

The global CBD oil market in the MEA will have a small share over the forecast period for illegal usage of marijuana, adverse effects of cannabis, and strict government policies. 

Browse Complete Report : https://www.marketresearchfuture.com/reports/cbd-oil-market-7355

Key Players

Key players profiled in the global CBD oil market report include Kazmira LLC (US), Curaleaf Holdings, Inc. (US), MedMen Enterprises Inc. (US), Aurora Cannabis (US), Canopy Growth Corporation (US), Medical Marijuana, Inc. (US), CV Sciences, Inc. (US), CBD American Shaman (US), ENDOCA (Netherlands), Charlotte's Web Holdings, Inc. (US), Green Roads of Florida, LLC (US), Freedom Leaf, Inc. (US), Folium Biosciences (US), and Aphria Inc. (Canada). 


Industry News

January 2020: Kadenwood, LLC, has launched Level Select CBD oil drops in three levels of intensity. It has CBD oil in the purest form sans any tetrahydrocannabinol and made through the company’s unique production technology. 




Posted by at No comments:

Cervical Fusion Market Application: Historical, Current and Projected Market Size, Competitive landscape & Forecast 2023



Cervical Fusion Market Application Research Report, by Fusion Type (Interbody and Anterior), Type (Metal, Polymer), Surgery (Minimally Invasive Spine Surgery, Open Spine Surgery), End User (Orthopaedic Clinics, Multispecialty Hospitals)  – Global Forecast till 2023

Market Analysis 

The global Cervical Fusion Market Application is predicted to grow at a striking CAGR over the forecast period (2017-2023), in accordance with the latest Market Research Future (MRFR) report. Cervical fusion, simply put, is a surgery which helps in joining selected bones in the cervical spine (neck). This surgery is generally needed when the discs between each vertebra and the cervical vertebrae get damaged due to chronic wear-and-tear or an injury. There are different methods to perform a cervical fusion surgery such as using an artificial graft made of metals or other polymers or inserting a bone graft for natural bone regrowth. 

Various factors are propelling the Cervical Fusion Market Application growth. These factors, as stated by the latest MRFR report, include increasing prevalence of rheumatoid arthritis and osteoarthritis, growing aging population, advent of cervical surgery techniques that are technologically advanced, increasing incidences of cervical disorders, growing cases of cancer and extensive research and development activities to diagnose and treat cancer, and increasing funds for healthcare by government organizations. 

On the flip side, the high price of treatments, complications related to the cervical surgery, and the high price of the diagnostic procedure are factors that may deter the Cervical Fusion Market Application growth over the forecast period. 

Market Segmentation

The MRFR report provides a complete segmental analysis of the Cervical Fusion Market Application report on the basis of end user, surgery, type, and fusion type. 

Based on fusion type, the Cervical Fusion Market Application is segmented into posterior fusion, anterior cervical fusion, anterior interbody fusion, and others. The interbody cervical fusion segment is again segmented into bone interbody cervical fusion, non-bone interbody cervical fusion, and others. 

Based on type, the Cervical Fusion Market Application is segmented into polymeric type, metal type, and others. 

Based on surgery, the Cervical Fusion Market Application is segmented into open spine surgery, minimally invasive spine surgery, and others. 

Based on end user, the Cervical Fusion Market Application is segmented into neurology clinics, multispecialty hospitals, orthopedic clinics, and others. 



Regional Analysis

By region, the Cervical Fusion Market Application report covers the latest trends and growth opportunities across Europe, the Americas, the Asia Pacific, and the Middle East and Africa. Of these, the Americas will lead the market over the forecast period. This is on account of increasing awareness about preventive care treatments to prevent spinal deformities and increasing incidences of spinal deformities amongst the older population. 

The Cervical Fusion Market Application in Europe is predicted to have the second-largest share in the market over the forecast period. This is on account of growing incidences of osteoarthritis and rheumatoid arthritis and rising geriatric population. 

The Cervical Fusion Market Application in the APAC region is predicted to grow at the fastest pace over the forecast period. This is owing to rapid expansions by leading players for market development and the growing adoption of cervical fusion surgeries. Japan is the chief contributor in this region owing to the remarkable rise in the adoption of cervical fusion surgeries due to presence of high aging population. 

The Cervical Fusion Market Application in the Middle East and Africa is predicted to have steady growth during the forecast period. This is on account of the rising emphasis on R&D activities in the healthcare sector and extensive growth of healthcare infrastructure. 

Key Players

Leading players profiled in the Cervical Fusion Market Application report include Shanghai Microport Orthopedics (China), Medacta (US), BAUMER (Switzerland), Medicrea Technologies UK Ltd (UK), B. Braun Melsungen AG (Germany), ArthroCare Corporation (US), Exactech, Inc. (US), RTI Surgical, Inc. (US), AMEDICA Corporation (US), LDR Holding Corporation (US), Integra LifeSciences Corporation (US), K2M, Inc. (US), Pioneer Surgical Technology Spine (US), Alphatec Spine, Inc. (US), Zimmer Holdings, Inc. (US), Biomet, Inc. (US), Orthofix Holdings, Inc. (US), Globus Medical Inc. (US), NuVasive, Inc. (US), Stryker Corporation (US), Synthes, Inc. (US), DePuy Spine, Inc. (US), and Medtronic, Inc. (US). 

June 2019: ChoiceSpine LLC has received FDA clearance for marketing its Boomerang Anterior Cervical Plate and Tiger Shark C interbody device for use separately or together in the cervical spinal fusion procedure. 
Posted by at No comments:

Cervical Fusion Market Application Overview, Dynamics, Growth Factors for Business Expansion, Key Companies, Trends and Forecast 2023

Cervical Fusion Market Application Research Report, by Fusion Type (Interbody and Anterior), Type (Metal, Polymer), Surgery (Minimally Invasive Spine Surgery, Open Spine Surgery), End User (Orthopaedic Clinics, Multispecialty Hospitals)  – Global Forecast till 2023

Market Analysis 

The global Cervical Fusion Market Application is predicted to grow at a striking CAGR over the forecast period (2017-2023), in accordance with the latest Market Research Future (MRFR) report. Cervical fusion, simply put, is a surgery which helps in joining selected bones in the cervical spine (neck). This surgery is generally needed when the discs between each vertebra and the cervical vertebrae get damaged due to chronic wear-and-tear or an injury. There are different methods to perform a cervical fusion surgery such as using an artificial graft made of metals or other polymers or inserting a bone graft for natural bone regrowth. 

Various factors are propelling the Cervical Fusion Market Application growth. These factors, as stated by the latest MRFR report, include increasing prevalence of rheumatoid arthritis and osteoarthritis, growing aging population, advent of cervical surgery techniques that are technologically advanced, increasing incidences of cervical disorders, growing cases of cancer and extensive research and development activities to diagnose and treat cancer, and increasing funds for healthcare by government organizations. 

On the flip side, the high price of treatments, complications related to the cervical surgery, and the high price of the diagnostic procedure are factors that may deter the Cervical Fusion Market Application growth over the forecast period. 

Market Segmentation

The MRFR report provides a complete segmental analysis of the Cervical Fusion Market Application report on the basis of end user, surgery, type, and fusion type. 

Based on fusion type, the Cervical Fusion Market Application is segmented into posterior fusion, anterior cervical fusion, anterior interbody fusion, and others. The interbody cervical fusion segment is again segmented into bone interbody cervical fusion, non-bone interbody cervical fusion, and others. 

Based on type, the Cervical Fusion Market Application is segmented into polymeric type, metal type, and others. 

Based on surgery, the Cervical Fusion Market Application is segmented into open spine surgery, minimally invasive spine surgery, and others. 

Based on end user, the Cervical Fusion Market Application is segmented into neurology clinics, multispecialty hospitals, orthopedic clinics, and others. 



Regional Analysis

By region, the Cervical Fusion Market Application report covers the latest trends and growth opportunities across Europe, the Americas, the Asia Pacific, and the Middle East and Africa. Of these, the Americas will lead the market over the forecast period. This is on account of increasing awareness about preventive care treatments to prevent spinal deformities and increasing incidences of spinal deformities amongst the older population. 

The Cervical Fusion Market Application in Europe is predicted to have the second-largest share in the market over the forecast period. This is on account of growing incidences of osteoarthritis and rheumatoid arthritis and rising geriatric population. 

The Cervical Fusion Market Application in the APAC region is predicted to grow at the fastest pace over the forecast period. This is owing to rapid expansions by leading players for market development and the growing adoption of cervical fusion surgeries. Japan is the chief contributor in this region owing to the remarkable rise in the adoption of cervical fusion surgeries due to presence of high aging population. 

The Cervical Fusion Market Application in the Middle East and Africa is predicted to have steady growth during the forecast period. This is on account of the rising emphasis on R&D activities in the healthcare sector and extensive growth of healthcare infrastructure. 

Key Players

Leading players profiled in the Cervical Fusion Market Application report include Shanghai Microport Orthopedics (China), Medacta (US), BAUMER (Switzerland), Medicrea Technologies UK Ltd (UK), B. Braun Melsungen AG (Germany), ArthroCare Corporation (US), Exactech, Inc. (US), RTI Surgical, Inc. (US), AMEDICA Corporation (US), LDR Holding Corporation (US), Integra LifeSciences Corporation (US), K2M, Inc. (US), Pioneer Surgical Technology Spine (US), Alphatec Spine, Inc. (US), Zimmer Holdings, Inc. (US), Biomet, Inc. (US), Orthofix Holdings, Inc. (US), Globus Medical Inc. (US), NuVasive, Inc. (US), Stryker Corporation (US), Synthes, Inc. (US), DePuy Spine, Inc. (US), and Medtronic, Inc. (US). 

June 2019: ChoiceSpine LLC has received FDA clearance for marketing its Boomerang Anterior Cervical Plate and Tiger Shark C interbody device for use separately or together in the cervical spinal fusion procedure. 
Posted by at No comments:
Subscribe to: Posts (Atom)